To enhance reliability, guidelines have been introduced for HER2 and ER/PR testing [7,8], but challenges remain with the Ki67 marker’s inconsistent assessment, hindering its precise, routine diagnostic use for classifying breast carcinomas into Luminal A and Luminal B subtypes. Here, ESR1 is linked to breast carcinoma.